Overview

A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

Status:
Recruiting
Trial end date:
2028-10-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn about the safety and side effects of combining entinostat, an investigational drug, with capecitabine, a drug commonly used in breast cancer (BC), in both participants with metastatic breast cancer (MBC) and then participants with high-risk breast cancer after neo-adjuvant therapy.
Phase:
Phase 1
Details
Lead Sponsor:
University of Virginia
Collaborator:
Syndax Pharmaceuticals
Treatments:
Capecitabine
Entinostat